Top Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Your Basket's Financial Footprint
Summary and key takeaways for a basket of top biotech stocks based on provided market capitalisation data.
- Large-cap dominance tends to provide stability and lower volatility, making performance similar to broad-market exposure.
- Suitable as a core holding in a diversified portfolio; not intended as a speculative, high-risk trade.
- More likely to deliver steady, long-term value rather than rapid, short-term gains.
AMGN: $162.12B
GILD: $153.96B
BIIB: $21.44B
- Other
About This Group of Stocks
Our Expert Thinking
These biotech companies are pioneering revolutionary treatments using advanced technologies like CRISPR gene editing. With favorable regulatory environments expediting approvals and growing global demand for innovative healthcare solutions, this sector offers both meaningful impact and promising financial growth opportunities.
What You Need to Know
Biotech investments can offer substantial returns but typically involve longer development cycles. The industry is projected to grow from $1.55 trillion in 2023 to approximately $3.88 trillion by 2030, with regulatory support accelerating the approval of promising treatments.
Why These Stocks
We've selected established biotech leaders and innovative disruptors working on groundbreaking medical advancements. These companies are well-positioned to respond to increasing healthcare demands as global populations age, making them potentially valuable additions to a forward-looking investment portfolio.
Why You'll Want to Watch These Stocks
Medical Game-Changers
These companies are developing treatments that could transform healthcare as we know it. From gene editing to novel therapies, they're tackling our biggest health challenges.
Explosive Growth Potential
The biotech industry is projected to grow at nearly 14% annually through 2030. Getting in now means positioning yourself at the start of what could be a remarkable expansion.
More Than Just Profits
By investing in biotech, you're not just seeking returns but also supporting companies developing treatments that could save millions of lives and improve countless others.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Boeing Forced Sale Impact | Defense Stocks 2025
The FTC's requirement for Boeing to sell parts of Spirit AeroSystems to approve their merger opens up the aerospace supply chain. This creates investment opportunities in other component manufacturers and defense contractors poised to benefit from a more competitive landscape.
Media Takeover Race Heats Up in 2025
Paramount Skydance has intensified the bidding war for Warner Bros. Discovery by increasing its breakup fee, signaling a strong commitment to the acquisition. This highlights a broader trend of consolidation in the media sector, creating potential opportunities among other content producers and M&A service providers.
EU Meta AI Probe: What's Next for Tech Competition
The EU is investigating Meta's practice of blocking rival AI chatbots on WhatsApp, raising significant antitrust concerns. This regulatory pressure could force open the ecosystem, creating a major growth opportunity for independent AI developers and challenging the dominance of Big Tech gatekeepers.